Express Mail No.: **EV 535 904 243 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Bhagwat et al.	Confirmation No.: 1280
Serial No.: 10/673,121	Group Art Unit: 1617
Filed: September 26, 2003	Examiner: Kim, Jennifer M.
For: INDAZOLE DERIVATIVES AS JNK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO	Attorney Docket No.: 10624-133-999 (CAM: 700755-999132)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or might be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A07**, which are listed on the accompanying Substitute for Form 1449/PTO entitled "Information Disclosure Statement By Applicant." A copy of references **A01-A07** are submitted herewith.

Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review references **A01-A07** and make them of record in the file history of the above-identified application by initializing the attached Substitute for Form 1449/PTO entitled "Information Disclosure Statement By Applicant."

As this Supplemental Information Disclosure Statement is being submitted before the mailing of any final action under § 1.113, a notice of allowance under § 1.311, or an

action that otherwise closes prosecution in the application, it is estimated that a fee of $180.00 is due pursuant to 37 C.F.R. §§ 1.97(c)(2) and 1.17(p). Please charge the required fee to Jones Day Deposit Account No. 50-3013. Should the Patent and Trademark Office determine that any additional fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this document is enclosed for accounting purposes.

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

By: Michael J. Bruner, Reg. No. 47,458

Date: August 24, 2006

By: Michael J. Bruner (Reg. No. 47,458)
JONES DAY
222 East 41st Street
New York, New York 10017
(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12750 High Bluff Drive, Suite 300
San Diego, California 92130
(858) 314-1130

Enclosures

Express Mail No.: **EV 535 904 243 US**

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 10624-133-999	APPLICATION NO. 10/673,121
	APPLICANT Bhagwat et al.	CONF. NO. 1280
	FILING DATE September 26, 2003	GROUP 1617

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER REFERENCES (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	A01	Burgess *et al.*, 1998, "Regulation of the c-*jun* Gene in p210 BCR-ABL Transformed Cells Corresponds With Activity of JNK, the c-*jun* N-Terminal Kinase," *Blood 92(7)*:2450-2460.
	A02	Cripe *et al.*, 2002, "Role for c-*jun* N-terminal kinase in treatment-refractory acute myeloid leukemia (AML) signaling to multidrug-efflux and hyperproliferation," *Leukemia 16*: 799-812.
	A03	Hess *et al.*, 2002, Survival signaling mediated by c-Jun NH_2-terminal kinase in transformed B lymphoblasts," *Nature Genetics 32*:201-205.
	A04	Bost *et al.*, 1999, "The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells," *Molecular and Cellular Biology19(3)*:1938-1949
	A05	Yang *et al.*, 2003, "C-Jun NH_2-terminal Kinase Mediates Proliferation and Tumor Growth of Human Prostate Carcinoma," *Clinincal Cancer Research 9*:391-401.
	A06	Tsuuiki *et al.*, 2003, "Constitutively Active Forms of c-Jun NH_2-terminal Kinase Are Expressed in Primary Glial Tumors," *Cancer Research 63*:250-255.
	A07	Potapova *et al.*, 2000, "c-Jun N-terminal Kinase Is Essential for Growth of Human T98G Glioblastoma Cells," *J. Biol. Chem. 275(32)*:24767-24775.

EXAMINER	**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not
in conformance and not considered. Include copy of this form with next communication to applicant.